组织活检与液体活检在前列腺癌中可能互补
Tissue and Liquid Biopsies May Complement Each Other in Prostate Cancer
一项分析发现,350名转移性去势抵抗性前列腺癌患者在不同种族群体中可操作的基因突变、肿瘤突变负荷和循环肿瘤DNA比例无显著差异。研究显示组织活检与液体活检在突变检测上存在差异,提示两种检测方法可能互补,有助于识别更多可操作突变并指导靶向治疗。
— Analysis found no significant differences in genomic alterations across ethnic groups
by Gregory Laub, Senior Director, Video, MedPage Today
November 17, 2026 • 3 min read
An analysis of patients with metastatic castration-resistant prostate cancer presented at the European Society for Medical Oncology (ESMO) congress found no statistically significant differences in actionable genomic alterations, tumor mutational burden (TMB), or circulating tumor (ct)DNA fraction across ethnic groups. The findings also showed differences in mutation detection between tissue and liquid biopsies, suggesting the two testing methods may provide complementary information.
In this exclusive MedPage Today video, Virginia Yuk-Chun Lam, an MD candidate at King's College London, discusses the findings and their potential implications for identifying actionable mutations and guiding targeted treatment.
Following is a transcript of her remarks:
What we did this year is we looked at 350 patients with prostate cancer. They all have castration-resistant prostate cancer and had one line of ARPI [androgen receptor pathway inhibitor] and progressed.
So what we did is we looked at both the tissue and the ctDNA to check if they've got any actionable genomic mutations and looked at their tumor mutation burden and also their ctDNA fractions.
The reason we are particularly interested in this group of patients is we know that there are some ethnicity differences, and also where I'm based in Guy's Hospital, it is a very diverse population with a high number of Black [patients]. So we would like to see if there's any ethnicity differences in those kinds of actionable mutations, TMB, and also ctDNA fractions.
So what we found out is the actionable mutation BRAF is kind of numerically higher in Black patients. The highest numbers of mutations were TP53; however, there's no ethnicity differences in them. For the patients with aggressive mutations in TP53, RB1, and PTEN, there's no particular differences in the ethnicity either. But with all of these, there's no statistical differences in all of these patients, but BRAF is numerically higher.
The next thing we also looked at is the mutational burden to see if there's any ethnicity differences. And what we found out is that between the tissue and the ctDNA, they are higher in the ctDNA fractions, which we kind of expected because when we looked at the ctDNA, we know they pick up a little bit more and also when the ctDNA is taken, that is when they progress.
The last thing we looked at is to try to match the ctDNA fraction and the tissue concordances to see if we pick up higher concordances in certain kinds of mutations. In our 101 patients, they got paired samples. We found out there's high concordances in BRCA and also patients with aggressive mutations. However, in PTEN, there's low concordances, but mainly they're picked up by the ctDNA.
So that's kind of a top four of what we presented at ESMO this year. And from what we can make a conclusion of it, it is a single-center cohort, we would like to extend it to a multicenter cohort with a wider ethnicity as well. Statistically, there's no big differences amongst the actionable mutation, TMB, and also ctDNA fractions. However, numerically we know it is higher in BRCA1/2, and we also found out that PTEN, as I say, is better picked up in ctDNA.
So we hope that in the future these two modalities can help each other to pick up the most actionable mutations and can benefit to see if we can find targeted drugs for the patients who progress in this kind of cohort.
I know especially in the U.K. sometimes we don't do it together. A lot of time we do tissue at diagnosis and ctDNA when they progress. But I think we found that both modalities are important. So if we can, we can try to do both.
But I know probably in other countries, say in the U.S., you've got a little bit more resources and you might tend to do both, but in other settings, this is kind of an insight that we can consider both as a way to find the most targeted actionable mutations to targeted drugs.
来源:MedPage Today · medpagetoday.com